Fisher Asset Management LLC Has $16.15 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Fisher Asset Management LLC raised its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 44.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 792,499 shares of the company’s stock after buying an additional 245,168 shares during the period. Fisher Asset Management LLC’s holdings in Denali Therapeutics were worth $16,151,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its position in Denali Therapeutics by 163.7% in the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock valued at $1,162,000 after buying an additional 24,767 shares in the last quarter. FMR LLC boosted its position in Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after buying an additional 7,596,508 shares in the last quarter. Algert Global LLC boosted its position in Denali Therapeutics by 82.4% in the third quarter. Algert Global LLC now owns 48,630 shares of the company’s stock valued at $1,417,000 after buying an additional 21,975 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Denali Therapeutics by 6.5% during the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock worth $6,857,000 after purchasing an additional 14,324 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock valued at $36,076,000 after purchasing an additional 149,939 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the transaction, the director now directly owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve E. Krognes sold 3,339 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the transaction, the director now directly owns 25,757 shares of the company’s stock, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,940 shares of company stock valued at $973,442. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Stock Down 8.2 %

Shares of Denali Therapeutics stock opened at $15.20 on Tuesday. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33. The business has a fifty day simple moving average of $21.29 and a 200 day simple moving average of $24.57. The stock has a market cap of $2.19 billion, a PE ratio of -5.51 and a beta of 1.43.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08. Analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on DNLI shares. JPMorgan Chase & Co. dropped their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a research report on Friday. Oppenheimer dropped their target price on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a research report on Monday. The Goldman Sachs Group dropped their target price on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Finally, Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 7th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.77.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.